Earnings due 24 Mar: NWRN.SW Newron Pharmaceuticals S.p.A. (SIX) pipeline test

The NWRN.SW stock trades intraday at CHF 15.40 as investors prepare for Newron Pharmaceuticals S.p.A.’s earnings on 24 Mar 2026. Traders will watch revenue, pipeline updates and guidance. Intraday volume is 140,163 shares and the move today links directly to upcoming clinical milestones and the company’s valuation on the SIX exchange in Switzerland.

Earnings preview and calendar for NWRN.SW stock

Newron reports results on 24 Mar 2026, making earnings the immediate catalyst for NWRN.SW stock. The market will focus on revenue, R&D spend and any update on Xadago, Evenamide or Ralfinamide programs. One clear near-term metric is EPS history: trailing EPS is 1.23 with a trailing PE of 11.87.

Analysts and traders should note the announcement time and prepare for intraday volatility. With shares at CHF 15.40, even modest guidance shifts can move price 5.00% or more in either direction.

Intraday price action, volume and short-term context for NWRN.SW stock

Today NWRN.SW opened at CHF 14.50, hit a day low of CHF 13.78, and traded up to CHF 15.40 on volume 140,163. The 1‑day change is +2.39%, and average volume is 146,179, so liquidity is typical for Swiss small‑caps.

Price sits below the 50‑day average (CHF 20.28) but above the 200‑day average (CHF 14.38). That mix explains why intraday traders are active: momentum indicators point to oversold readings while medium‑term bias remains mixed.

Fundamentals and valuation snapshot for NWRN.SW stock

Newron shows a market cap near CHF 291.43M and revenue per share TTM 2.9998, with net income per share 1.2688. Key ratios: PE (reported) 11.87, price/sales 5.34, and price/book 202.23. Return on equity is 16.66%, and current ratio is 1.51, indicating moderate liquidity.

Compared with the Healthcare sector average PE of 26.77, NWRN.SW stock trades at a material discount on earnings. Investors should weigh that against a high price/book which reflects low reported book equity per share.

Technicals and trading signals for NWRN.SW stock

Technical indicators show NWRN.SW is oversold intraday: RSI 20.12, Stochastic %K 5.04, and Williams %R -97.84. Bollinger Band middle is CHF 17.50 and lower band CHF 14.76, so current price is near the lower band.

Short‑term momentum is negative (MACD histogram -0.20) but the 200‑day average lies below current price, offering a potential support zone. Traders should use tight risk controls ahead of earnings given ATR 1.08.

Meyka grade and forecast for NWRN.SW stock

Meyka AI rates NWRN.SW with a score out of 100: 76.15 | Grade B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a 12‑month price of CHF 23.38. At the current price of CHF 15.40 that implies an upside of 51.84%. Forecasts are model‑based projections and not guarantees. Use this as one input within a broader investment process.

Risks, catalysts and sector context for NWRN.SW stock

Major risks include clinical trial setbacks, regulatory delays, and licensing outcomes that directly affect valuation. R&D accounts for ~22.36% of revenue, underlining pipeline dependence.

Catalysts: the 24 Mar earnings call, trial readouts and any Xadago label or market updates. Sector context: Healthcare in Switzerland has a 1‑year average PE of 26.77, so Newron’s lower PE may attract value‑focused biopharma investors if pipeline risk eases.

Final Thoughts

Short‑term traders should expect elevated intraday volatility in NWRN.SW stock as Newron Pharmaceuticals releases earnings on 24 Mar 2026. At CHF 15.40 the shares sit below the 50‑day average but above the 200‑day average, a mixed technical picture. Fundamentals show trailing EPS 1.23 and a PE near 11.87, cheaper than the Healthcare peer group on earnings but stretched on price/book. Meyka AI’s forecast model projects CHF 23.38 over 12 months, an implied upside of 51.84%, while our proprietary grade scores the stock 76.15/100 (B+, BUY). That combination frames a trade‑vs‑invest decision: event traders can target earnings‑driven moves with strict stops, while longer‑term investors should monitor pipeline progress and cash flow metrics. Use company releases and the earnings call to update assumptions before reallocating capital. For intraday updates see the Newron site source and the company LinkedIn source. Meyka AI provides this as AI‑powered market analysis and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.